Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 15.49% is 76% above its 5-year average of 8.83%, near the high end of its 5-year range (4.40%–15.49%).
40.31% above its 12-month average of 11.04%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
15.49%
RETURN ON ASSETS (ROA) AVG TTM
11.04%
RETURN ON ASSETS (ROA) AVG 3Y
9.26%
RETURN ON ASSETS (ROA) AVG 5Y
8.83%
RETURN ON ASSETS (ROA) AVG 10Y
0.82%
RETURN ON ASSETS (ROA) AVG 15Y
-7.74%
RETURN ON ASSETS (ROA) AVG 20Y
-29.13%
CURRENT VS TTM AVG
+40.31%
CURRENT VS 3Y AVG
+67.23%
CURRENT VS 5Y AVG
+75.52%
CURRENT VS 10Y AVG
+1799.55%
CURRENT VS 15Y AVG
+300.22%
CURRENT VS 20Y AVG
+153.17%
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+201.36%
vs the sector median at left
DexCom, Inc.
Market Cap
$31.90B
Return on Assets (ROA)
15.49%
TTM Avg
11.04%
3Y Avg
9.26%
5Y Avg
8.83%
Market Cap
$31.90B
Return on Assets (ROA)
-6.14%
TTM Avg
-2.29%
3Y Avg
0.04%
5Y Avg
0.75%
Market Cap
$32.06B
Return on Assets (ROA)
16.99%
TTM Avg
17.06%
3Y Avg
15.57%
5Y Avg
14.60%
Market Cap
$31.40B
Return on Assets (ROA)
2.60%
TTM Avg
5.11%
3Y Avg
6.74%
5Y Avg
8.29%
Market Cap
$30.86B
Return on Assets (ROA)
17.35%
TTM Avg
17.37%
3Y Avg
16.33%
5Y Avg
15.33%
Market Cap
$30.16B
Return on Assets (ROA)
4.27%
TTM Avg
5.83%
3Y Avg
5.87%
5Y Avg
14.86%
Market Cap
$30.13B
Return on Assets (ROA)
0.67%
TTM Avg
13.34%
3Y Avg
15.53%
5Y Avg
17.15%
Market Cap
$29.33B
Return on Assets (ROA)
1.76%
TTM Avg
3.17%
3Y Avg
1.75%
5Y Avg
1.75%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | $31.90B | 15.49% | 11.04% | 9.26% | 8.83% |
| Centene Corp. (CNC)vs › | $31.90B | -6.14% | -2.29% | 0.04% | 0.75% |
| ResMed Inc. (RMD)vs › | $32.06B | 16.99% | 17.06% | 15.57% | 14.60% |
| Biogen Inc. (BIIB)vs › | $31.40B | 2.60% | 5.11% | 6.74% | 8.29% |
| Zoetis Inc. (ZTS)vs › | $30.86B | 17.35% | 17.37% | 16.33% | 15.33% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $30.16B | 4.27% | 5.83% | 5.87% | 14.86% |
| Waters Corporation (WAT)vs › | $30.13B | 0.67% | 13.34% | 15.53% | 17.15% |
| Alcon Inc. (ALC)vs › | $33.71B | 2.06% | 3.23% | 2.72% | 1.72% |
| Medline Inc. (MDLN)vs › | $29.33B | 1.76% | 3.17% | 1.75% | 1.75% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $34.80B | 14.54% | -0.12% | -10.91% | -15.37% |
ROA
15.5%
ROE
38.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 13.19% |
| 2024-12-31 | 8.89% |
| 2023-12-31 | 8.64% |
| 2022-12-31 | 6.33% |
| 2021-12-31 | 4.40% |
| 2020-12-31 | 11.50% |
| 2019-12-31 | 4.22% |
| 2018-12-31 | -6.63% |
| 2017-12-31 | -5.55% |
| 2016-12-31 | -16.29% |
| 2015-12-31 | -19.73% |
| 2014-12-31 | -12.13% |
| 2013-12-31 | -24.33% |
| 2012-12-31 | -51.42% |
| 2011-12-31 | -37.14% |
| 2010-12-31 | -71.50% |
| 2009-12-31 | -114.01% |
| 2008-12-31 | -124.38% |
| 2007-12-31 | -59.38% |
| 2006-12-31 | -72.19% |
| 2005-12-31 | -54.24% |
| 2004-12-31 | -47.51% |
| 2003-12-31 | -47.74% |
| 2002-12-31 | 0.00% |
| 2001-12-31 | -72.60% |
| 2000-12-31 | -27.61% |
